Conexeu Sciences Stock
Conexeu Sciences Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Miles Harrison
- Employees
- 4
- Market cap
- $86 M
- IPO
- 21/05/2026
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates…
Conexeu Sciences stock: price history
1D
-22.5%
1W
-21.3%
1M
-33.8%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~16% stronger price swings than usual
Ask the agents about Conexeu Sciences
Analyst assessment of Conexeu Sciences
PRICE TARGET LOW
US$20.00
CONSENSUS
US$20.00
MEDIAN
US$20.00
PRICE TARGET HIGH
US$20.00
No current analyst ratings available.
Free float & liquidity
FREE FLOAT
55.1%
FLOAT SHARES
15,541,609
AVG. DAILY VOLUME (30D)
279,896
Insider transactions (SEC)
Bogart David Robert
Sharpe Jeffrey Nathan
Purcell Lynn Sebastian
Purcell Lynn Sebastian
Wright Michael G.
Comparable stocks
Frequently asked questions about Conexeu Sciences stock
What does Conexeu Sciences do?
Conexeu Sciences Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Miles Harrison, the company employs around 4 people.
The IPO was on 21/05/2026; the stock trades on NASDAQ under the ticker CNXU.
What do analysts say about Conexeu Sciences stock?
The average price target is US$20.00, ranging from US$20.00 to US$20.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Conexeu Sciences report next?
Around past earnings, price swings were roughly 16% stronger than usual.
Does Conexeu Sciences pay a dividend?
No, Conexeu Sciences currently does not pay a dividend.
Which stocks are comparable to Conexeu Sciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Conexeu Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Conexeu Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.